This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Friedberg, J. W. Articles by Chengazi, V. Search for Related Content PubMed PubMed Citation Articles by Friedberg, J. W. Articles by Chengazi, V.

PET Scans in the Staging of Lymphoma: Current Status

Lymphoma Program, James P. Wilmot Cancer Center, University of Rochester, Rochester, New York, USA

Correspondence: Jonathan W. Friedberg, M.D., 601 Elmwood Avenue, Box 704, Rochester, New York 14642, USA. Telephone: 585-273-4150; Fax: 585-506-0337; e-mail: Jonathan_Friedberg{at}urmc.rochester.edu

Positron emission tomography (PET) is a novel functional imaging technique that provides several inherent advantages over conventional nuclear scintigraphy. Several studies have suggested a role for PET using the positron emitter fluorine-18 in the diagnosis and follow-up of patients with lymphoma. This review summarizes the existing data evaluating the role of 2-fluoro-2-deoxy-D-glucose (FDG)-PET in both the staging and follow-up of patients with lymphoma. Most studies of PET involve patients with either Hodgkin’s disease or diffuse large B-cell non-Hodgkin’s lymphoma. PET detects more disease sites above and below the diaphragm on staging of lymphoma than gallium scintigraphy and may have particular utility in the evaluation of the spleen. Moreover, persistently positive PET scans during and after chemotherapy appear to have a high sensitivity for predicting subsequent relapse. A negative PET scan at the end of therapy provides very favorable prognostic information. Persistently positive PET scans at the end of therapy warrant close follow-up or additional diagnostic procedures, since some of those patients may remain in prolonged remission. Clearly, additional studies, including prospective blinded trials and cost-effectiveness analyses, are warranted to determine which subsets of patients with lymphoma ultimately will benefit from this modality.

Key Words. FDG-PET • Non-Hodgkin’s lymphoma • Gallium scintigraphy • Staging

This article has been cited by other articles:

				J. H. Mendler and J. W. Friedberg Salvage Therapy in Hodgkin's Lymphoma Oncologist, April 1, 2009; 14(4): 425 - 432. [Abstract] [Full Text] [PDF]

				J. W. Fletcher, B. Djulbegovic, H. P. Soares, B. A. Siegel, V. J. Lowe, G. H. Lyman, R. E. Coleman, R. Wahl, J. C. Paschold, N. Avril, et al. Recommendations on the Use of 18F-FDG PET in Oncology J. Nucl. Med., March 1, 2008; 49(3): 480 - 508. [Abstract] [Full Text] [PDF]

				S. Sasaki, N. Shikama, K. Koiwai, and M. Kadoya Relationship Between the Response to Treatment and the Prognosis of Patients with Aggressive Lymphomas Treated with Chemotherapy Followed by Involved-field Radiotherapy: Radiographic Assessment Jpn. J. Clin. Oncol., January 1, 2008; 38(1): 43 - 48. [Abstract] [Full Text] [PDF]

				P. Raanani, Y. Shasha, C. Perry, U. Metser, E. Naparstek, S. Apter, A. Nagler, A. Polliack, I. Ben-Bassat, and E. Even-Sapir Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era? Ann. Onc., January 1, 2006; 17(1): 117 - 122. [Abstract] [Full Text] [PDF]

				S. M. Ansell and J. Armitage Non-Hodgkin Lymphoma: Diagnosis and Treatment Mayo Clin. Proc., August 1, 2005; 80(8): 1087 - 1097. [Abstract] [PDF]

				R. Srinivasan, A. Filie, J. Reynolds, R. Chang, C. Chow, D. S. Schrump, Y. Takahashi, A. F. Suffredini, and R. W. Childs Positron Emission Tomography for Lymphoma Staging: Tissue Remains the Issue J Natl Cancer Inst, April 20, 2005; 97(8): 611 - 613. [Full Text] [PDF]

				K. P. Beal, H. W. Yeung, and J. Yahalom FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases Ann. Onc., March 1, 2005; 16(3): 473 - 480. [Abstract] [Full Text] [PDF]

				R. Kumar, Y. Xiu, S. Potenta, A. Mavi, H. Zhuang, J. Q. Yu, T. Dhurairaj, S. Dadparvar, and A. Alavi 18F-FDG PET for Evaluation of the Treatment Response in Patients with Gastrointestinal Tract Lymphomas J. Nucl. Med., November 1, 2004; 45(11): 1796 - 1803. [Abstract] [Full Text] [PDF]

				H. Schoder, S. M. Larson, and H. W.D. Yeung PET/CT in Oncology: Integration into Clinical Management of Lymphoma, Melanoma, and Gastrointestinal Malignancies J. Nucl. Med., January 1, 2004; 45(90010): 72S - 81. [Abstract] [Full Text] [PDF]